President Biden Signs Executive Order to Launch a National Biotechnology and Biomanufacturing Initiative
On Monday, September 12, 2022, President Joe Biden signed an Executive Order to launch a National Biotechnology and Biomanufacturing Initiative. The official White House correspondence emphasizes that “[t]his Initiative will create jobs at home, build stronger supply chains, and lower prices for American families.[1]" This Initiative is intended help the United States further expand its role in the global bioeconomy, and it is expected to bolster biotechnology innovation.
The primary aim of this Initiative is to make the United States less reliant on biomanufacturing products made outside the country and to become a key source of materials and bioproduction globally. With an increased awareness of the supply chain issues that have stalled and even threatened some segments of the health sector, this Initiative highlights the need for access to important chemicals and active pharmaceutical ingredients. The U.S. Department of Health and Human Services (HHS) will implement the Initiative by “Invest[ing] $40 million to expand the role of biomanufacturing for active pharmaceutical ingredients, antibiotics, and industrially relevant key starting materials needed to produce essential medications and respond to the current or a future pandemic.[2] ” These announcements indicate a renewed interest and efforts in fortifying the US biotechnology industry to foster medical breakthroughs.
The influx of investment into drug production infrastructure will likely decrease US reliance on foreign manufacturers of pharmaceutical and biotechnology products. For domestic producers, this will mean an increased focus by the FDA on better understanding the science of advanced manufacturing and more opportunities for pre-submission interactions for those involved in advanced manufacturing of pharmaceuticals and biologics. This can be inferred from HHS highlighting the FDA’s Platform Vector Gene Therapy (PaVe-GT) Pilot Project in their project plan. It will be interesting to see how the FDA carves out new pathways to approval and guidelines to help facilitate this Initiative.
Interested parties in the biotechnology industry may want to look into the Summit on the National Biotechnology and Biomanufacturing Initiative, which was held on September 14, 2022. Herein, the administration unveiled their biotechnology investment plans and resources.
[1] https://www.whitehouse.gov/briefing-room/statements-releases/2022/09/12/fact-sheet-president-biden-to-launch-a-national-biotechnology-and-biomanufacturing-initiative/?utm_source=link
[2] https://www.hhs.gov/about/news/2022/09/14/fact-sheet-hhs-takes-action-executive-order-launching-national-biotechnology-biomanufacturing-initiative.html
How Medmarc Can Help
Life sciences and medical technology companies face complex and evolving risks throughout the product lifecycle. Medmarc provides specialized life sciences insurance, medical device insurance, products liability coverage, and risk management expertise to address the unique exposures of the industry. From emerging technologies and clinical trials to products on the market, Medmarc combines decades of life sciences experience with specialized industry knowledge and insurance solutions.
Explore Medmarc's insurance solutions to learn more about our capabilities, and talk with your insurance broker about your organization’s evolving risks and insurance considerations.
Phone: 888-633-6272
Copyright © 2026 - Medmarc
Related Articles
A Guide to FDA's Labeling Guidelines on Biosimilars and the Implications for Products Liability
The field of biopharmaceuticals has witnessed significant advancements in recent years,...FDA’s Drug, Biologics Centers Release Primary Bayesian Guidance
The FDA’s centers for pharmaceuticals and biologics have released a draft guidance specific to...Medmarc is a proud member of TDC Specialty. TDC Specialty is the marketing name for the specialty insurance operations and services of The Doctors Company and its subsidiaries and affiliated companies, including TDC Specialty Underwriters, Inc., TDC Specialty Insurance Company, TDC National Assurance Company, Healthcare Risk Advisors, Inc., Hospitals Insurance Company, Inc., ProAssurance Specialty Insurance Company, NORCAL Specialty Insurance Company, and Medmarc Casualty Insurance Company. All products and services are written or provided by subsidiaries or affiliates of The Doctors Company. The Doctors Company does not underwrite excess and surplus lines insurance. Certain coverages may be provided through surplus lines insurance subsidiaries of The Doctors Company through licensed surplus lines brokers. Coverages may be underwritten by TDC Specialty Insurance Company, TDC National Assurance Company, Hospitals Insurance Company, Inc., ProAssurance Specialty Insurance Company, NORCAL Specialty Insurance Company, or Medmarc Casualty Insurance Company. Product summaries are for informational purposes only. Coverage is subject to the language of the policy as actually issued. Coverage, policy terms, and availability may vary by state.
TDC Specialty Underwriters, Inc., is based and domiciled in Connecticut; in California d/b/a Insurance City Solutions (license #0L85833) and in New York, d/b/a TDC Specialty Underwriters Services. Healthcare Risk Advisors, Inc., is based and domiciled in New York.
